| Predicate |
Object |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07B2200-13 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-197
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C237-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-167
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C235-74
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C235-52 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-197
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C237-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-16 |
| filingDate |
2007-12-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2016-01-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate |
2016-01-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CN-103951583-B |
| titleOfInvention |
A crystalline form of the inhibitor |
| abstract |
The present invention relates to (3S)-3-[N-(N'-(2-tert-butylphenyl)oxalyl)alanyl]amino-5-(2',3',5',6'- Crystalline form of tetrafluorophenoxy)-4-oxopentanoic acid (see formula I). The invention further relates to a pharmaceutical composition comprising this crystalline form and to the use of said pharmaceutical composition and said crystalline form in the treatment of various disorders, in particular in the treatment of liver fibrosis. |
| priorityDate |
2006-12-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |